TY - JOUR T1 - Initial Feasibility and Clinical Implementation of Daily MR-guided Adaptive Head and Neck Cancer Radiotherapy on a 1.5T MR-Linac System: Prospective R-IDEAL 2a/2b Systematic Clinical Evaluation of Technical Innovation JF - medRxiv DO - 10.1101/2020.06.22.20137554 SP - 2020.06.22.20137554 AU - Brigid A. McDonald AU - Sastry Vedam AU - Jinzhong Yang AU - Jihong Wang AU - Pamela Castillo AU - Belinda Lee AU - Angela Sobremonte AU - Yao Ding AU - Abdallah S.R. Mohamed AU - Peter Balter AU - Neil Hughes AU - Daniela Thorwarth AU - Marcel Nachbar AU - Marielle E.P. Philippens AU - Chris H.J. Terhaard AU - Daniel Zips AU - Simon Böke AU - Musaddiq J. Awan AU - John Christodouleas AU - Clifton D. Fuller A2 - , Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/01/2020.06.22.20137554.abstract N2 - Introduction This prospective study is the first report of daily adaptive radiotherapy (ART) for head & neck cancers (HNC) using a 1.5T MR-linac, with particular focus on safety & feasibility and dosimetric results of an on-line rigid registration-based adapt-to-position (ATP) workflow.Methods Ten HNC patients received daily ART on a 1.5T/7MV MR-linac, six using ATP only and four using ATP with one off-line adapt-to-shape re-plan. Setup variability with custom immobilization masks was assessed by calculating the average systematic error (M), standard deviation of the systematic error (∑), and standard deviation of the random error (σ) of the isocenter shifts. Quality assurance was performed with a cylindrical diode array using 3%/3mm γ criteria. Adaptive treatment plans were summed for each patient to compare delivered dose with planned dose from the reference plan. The impact of dosimetric variability between adaptive fractions on the summation plan doses was assessed by tracking the number of optimization constraint violations at each individual fraction.Results The random errors (mm) for the x, y, and z isocenter shifts, respectively, were M = − 0.3, 0.7, 0.1; ∑ = 3.3, 2.6, 1.4; and σ = 1.7, 2.9, 1.0. The median γ pass rate was 99.9% (range: 90.9%-100%). The differences between the reference and summation plan doses were within [-0.61%, 1.78%] for the CTV and [-11.74%, 8.11%] for organs at risk (OARs), though percent increases in OAR dose above 2% only occurred in three cases, each for a single OAR. All cases had at least two fractions with one or more constraint violations. However, in nearly all instances, constraints were still met in the summation plan despite multiple single-fraction violations.Conclusion Daily ART on a 1.5T MR-linac using an on-line ATP workflow is safe and clinically feasible for HNC and results in delivered doses consistent with planned doses.Competing Interest StatementB.A. McDonald reports grants from National Institutes of Health (NIH)/National Institute of Dental and Craniofacial Research (NIDCR) (1F31DE029093-01A1) and research support from a Dr. John J. Kopchick Fellowship via The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, during the conduct of the study; personal fees (travel funds and speaking honorarium) from Elekta AB, outside the submitted work. J. Yang reports grants from Elekta AB and personal fees (licensing royalties) from Varian Medical Systems, outside the submitted work. J. Wang reports grants from Elekta AB, outside the submitted work. A.S.R. Mohamed reports grants from NIH/NIDCR (3R01DE028290-01S1), outside the submitted work. P. Balter reports sponsored research agreements from Varian Associates and RaySearch Laboratories, outside the submitted work. D. Thorwarth reports grants from German Research Foundation (DFG) (ZI 736/2-1, TH 1528/6-1), non-financial support from Elekta AB (Stockholm, Sweden), non-financial support from Philips (Best, The Netherlands), during the conduct of the study; grants from Elekta AB (Stockholm, Sweden), non-financial support from PTW Freiburg, grants from Siemens Healthineers (Erlangen, Germany), outside the submitted work. M. Nachbar reports grants from DFG (ZI 736/2-1), non-financial support from Elekta AB (Stockholm, Sweden), non-financial support from Philips (Best, The Netherlands), during the conduct of the study; grants, personal fees (travel funds and speaking honoraria) and non-financial support from Elekta AB (Stockholm, Sweden), outside the submitted work. M.E.P. Philippens reports grants and non-financial support from Elekta AB (Stockholm, Sweden), non-financial support from Philips Healthcare (Best, The Netherlands), outside the submitted work. C.H.J. Terhaard reports personal fees (travel funds) from Elekta AB, outside the submitted work. D. Zips and S. Boeke report grants from DFG (ZI 736/2-1), non-financial support from Elekta AB (Stockholm, Sweden), non-financial support from Philips (Best, The Netherlands), during the conduct of the study; personal fees (travel funds and speaking honoraria), non-financial support and other from Elekta AB (Stockholm, Sweden), outside the submitted work. M.J. Awan reports personal fees from Elekta, outside the submitted work. J. Christodouleas is an employee of Elekta, Inc. and reports grants from NIH/NIDCR (1R01DE028290-01), during the conduct of the study. C.D. Fuller reports grants from NIH/NIDCR (1R01DE028290-01), NIH/National Cancer Institute (NCI) (R01CA218148), grants from NIH/National Institute of Biomedical Imaging and Bioengineering (R25EB025787), and grants from Elekta AB (funding for MOMENTUM clinical trial), during the conduct of the study; grants from Patient-centered Outcomes Research Institute (PCS-1609-36195), grants from NIH/NCI (1R01CA225190-01, 1R01CA214825-01, P30CA016672 (Cancer Center Support Grant via MD Anderson), P50CA097007-10), grants from NIH/NIDCR (1R01DE025248/R56DE025248), grants from Sister Institute Network Fund (MD Anderson), grants from National Science Foundation Division of Civil, Mechanical, and Manufacturing Innovation (CMMI 1933369), grants and personal fees (travel funds and speaking honoraria) from Elekta AB, outside the submitted work.Clinical TrialNCT04075305Funding StatementB.A. McDonald reports grants from National Institutes of Health (NIH)/National Institute of Dental and Craniofacial Research (NIDCR) (1F31DE029093-01A1) and research support from a Dr. John J. Kopchick Fellowship via The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, during the conduct of the study; personal fees (travel funds and speaking honorarium) from Elekta AB, outside the submitted work. J. Yang reports grants from Elekta AB and personal fees (licensing royalties) from Varian Medical Systems, outside the submitted work. J. Wang reports grants from Elekta AB, outside the submitted work. A.S.R. Mohamed reports grants from NIH/NIDCR (3R01DE028290-01S1), outside the submitted work. P. Balter reports sponsored research agreements from Varian Associates and RaySearch Laboratories, outside the submitted work. D. Thorwarth reports grants from German Research Foundation (DFG) (ZI 736/2-1, TH 1528/6-1), non-financial support from Elekta AB (Stockholm, Sweden), non-financial support from Philips (Best, The Netherlands), during the conduct of the study; grants from Elekta AB (Stockholm, Sweden), non-financial support from PTW Freiburg, grants from Siemens Healthineers (Erlangen, Germany), outside the submitted work. M. Nachbar reports grants from DFG (ZI 736/2-1), non-financial support from Elekta AB (Stockholm, Sweden), non-financial support from Philips (Best, The Netherlands), during the conduct of the study; grants, personal fees (travel funds and speaking honoraria) and non-financial support from Elekta AB (Stockholm, Sweden), outside the submitted work. M.E.P. Philippens reports grants and non-financial support from Elekta AB (Stockholm, Sweden), non-financial support from Philips Healthcare (Best, The Netherlands), outside the submitted work. C.H.J. Terhaard reports personal fees (travel funds) from Elekta AB, outside the submitted work. D. Zips and S. Boeke report grants from DFG (ZI 736/2-1), non-financial support from Elekta AB (Stockholm, Sweden), non-financial support from Philips (Best, The Netherlands), during the conduct of the study; personal fees (travel funds and speaking honoraria), non-financial support and other from Elekta AB (Stockholm, Sweden), outside the submitted work. M.J. Awan reports personal fees from Elekta, outside the submitted work. J. Christodouleas is an employee of Elekta, Inc. and reports grants from NIH/NIDCR (1R01DE028290-01), during the conduct of the study. C.D. Fuller reports grants from NIH/NIDCR (1R01DE028290-01), NIH/National Cancer Institute (NCI) (R01CA218148), grants from NIH/National Institute of Biomedical Imaging and Bioengineering (R25EB025787), and grants from Elekta AB (funding for MOMENTUM clinical trial), during the conduct of the study; grants from Patient-centered Outcomes Research Institute (PCS-1609-36195), grants from NIH/NCI (1R01CA225190-01, 1R01CA214825-01, P30CA016672 (Cancer Center Support Grant via MD Anderson), P50CA097007-10), grants from NIH/NIDCR (1R01DE025248/R56DE025248), grants from Sister Institute Network Fund (MD Anderson), grants from National Science Foundation Division of Civil, Mechanical, and Manufacturing Innovation (CMMI 1933369), grants and personal fees (travel funds and speaking honoraria) from Elekta AB, outside the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MD Anderson IRB provided approval for this research under the MOMENTUM observational clinical trial (institutional protocol number PA18-0341; NCT04075305).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for this analysis will be posted on NIH Figshare in the coming weeks. A data descriptor publication is currently being prepared. ER -